Analyst Price Target is $55.14
▲ +92.14% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Y-mAbs Therapeutics in the last 3 months. The average price target is $55.14, with a high forecast of $68.00 and a low forecast of $45.00. The average price target represents a 92.14% upside from the last price of $28.70.
Current Consensus is
The current consensus among 7 polled investment analysts is to buy stock in Y-mAbs Therapeutics. This Buy consensus rating has held steady for over two years.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.